{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T15:30:35Z","timestamp":1749223835053,"version":"3.40.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012752","name":"Elanco","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Multidrug resistance-1 (MDR1) mutant dogs have diminished or lack P-glycoprotein (Pgp) expression at the blood\u2013brain barrier and are therefore more susceptible to neurotoxicity caused by macrocyclic lactones and other Pgp substrates due to increased drug penetration into the brain. Therefore, the safety of products containing macrocyclic lactones are required to be evaluated in this sensitive population.\u00a0Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is a novel endectocide for monthly oral administration in dogs. As moxidectin is a macrocyclic lactone, Credelio Quattro was administered to homozygous MDR1 mutant Collie dogs to evaluate the safety of the product.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study employed a completely randomized and blinded design, where dogs were allocated to one of four treatment groups. A total of 32 dogs were divided into 4 groups (placebo control, 1\u00d7, 2\u00d7, or 5\u00d7, the maximum recommended labeled dose of Credelio Quattro) each consisting of 8 dogs. Treatment was administered on 3 consecutive occasions, 28\u00a0days apart. Dogs were evaluated pre-dose and through 72-h post-treatment using the avermectin sensitive (AVS) categories of seizures or convulsions, ataxia, depression, mydriasis, muscle tremors, and salivation\/drooling\/vomiting. The assessment of safety was based on AVS scores, general health observations, body weight, and physical examinations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Credelio Quattro was well tolerated with no serious adverse events. There were no incidents of seizures or convulsions, ataxia, mydriasis, or muscle tremors observed. Salivation\/drooling\/vomiting was the most frequent observation, occurring in all groups, and most frequently in the 5\u00d7 group. Vomiting is a dose-dependent effect observed for Credelio Quattro in healthy dogs and is therefore unlikely to represent a neurological effect in MDR1 dogs. Depression was observed in one dog in each of the 0\u00d7, 2\u00d7, and 5\u00d7 groups. This was likely a spurious result versus true toxicity, as the sign was subtle and occurred singularly including at 0\u00d7. For all AVS signs, the events were transient, and dogs recovered without any intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Credelio Quattro was well tolerated and is safe in MDR1 mutant dogs up to 5\u00d7 the maximum recommended dose following three consecutive monthly administrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s13071-025-06795-y","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:39:40Z","timestamp":1745426380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of Credelio Quattro\u2122 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) in homozygous MDR1-mutant collie dogs"],"prefix":"10.1186","volume":"18","author":[{"given":"Kari L.","family":"Riggs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinshuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"6795_CR1","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/0959-8049(95)00130-b","volume":"31","author":"AH Schinkel","year":"1995","unstructured":"Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ, Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer. 1995;31:1295\u20138. https:\/\/doi.org\/10.1016\/0959-8049(95)00130-b.","journal-title":"Eur J Cancer"},{"key":"6795_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.vetpar.2008.09.009","volume":"158","author":"KL Mealey","year":"2008","unstructured":"Mealey KL. Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharmacogenetics. Vet Parasitol. 2008;158:215\u201322. https:\/\/doi.org\/10.1016\/j.vetpar.2008.09.009.","journal-title":"Vet Parasitol"},{"key":"6795_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1006\/scbi.1997.0068","volume":"8","author":"AH Schinkel","year":"1997","unstructured":"Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 1997;8:161\u201370. https:\/\/doi.org\/10.1006\/scbi.1997.0068.","journal-title":"Semin Cancer Biol"},{"key":"6795_CR4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2174\/138920112800399301","volume":"13","author":"J Geyer","year":"2012","unstructured":"Geyer J, Janko C. Treatment of MDR1 mutant dogs with macrocyclic lactones. Curr Pharm Biotechnol. 2012;13:969\u201386. https:\/\/doi.org\/10.2174\/138920112800399301.","journal-title":"Curr Pharm Biotechnol"},{"key":"6795_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/01.cir.99.4.552","volume":"99","author":"MF Fromm","year":"1999","unstructured":"Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation. 1999;99:552\u20137. https:\/\/doi.org\/10.1161\/01.cir.99.4.552.","journal-title":"Circulation"},{"key":"6795_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2460\/ajvr.71.1.115","volume":"71","author":"JG Sherman","year":"2010","unstructured":"Sherman JG, Paul AJ, Firkins LD. Evaluation of the safety of spinosad and milbemycin 5-oxime orally administered to Collies with the MDR1 gene mutation. Am J Vet Res. 2010;71:115\u20139. https:\/\/doi.org\/10.2460\/ajvr.71.1.115.","journal-title":"Am J Vet Res"},{"key":"6795_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1365-2885.2008.00964.x","volume":"31","author":"M Martinez","year":"2008","unstructured":"Martinez M, Modric S, Sharkey M, Troutman L, Walker L, Mealey K. The pharmacogenomics of P-glycoprotein and its role in veterinary medicine. J Vet Pharmacol Ther. 2008;31:285\u2013300. https:\/\/doi.org\/10.1111\/j.1365-2885.2008.00964.x.","journal-title":"J Vet Pharmacol Ther"},{"key":"6795_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/jsap.12618","volume":"58","author":"O Campbell","year":"2017","unstructured":"Campbell O, de Lorimier LP, Mealey KL. Adverse reaction to apomorphine in a Collie homozygous for the ABCB1\u20131\u2206 (MDR1) mutation. J Small Anim Pract. 2017;58:119. https:\/\/doi.org\/10.1111\/jsap.12618.","journal-title":"J Small Anim Pract"},{"key":"6795_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/00008571-200111000-00012","volume":"11","author":"KL Mealey","year":"2001","unstructured":"Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics. 2001;11:727\u201333. https:\/\/doi.org\/10.1097\/00008571-200111000-00012.","journal-title":"Pharmacogenetics"},{"key":"6795_CR10","first-page":"12","volume":"3","author":"KL Mealey","year":"2016","unstructured":"Mealey KL. How should i treat dogs & cats with MDR1 mutation? Ther Briefs. 2016;3:12\u201323.","journal-title":"Ther Briefs"},{"key":"6795_CR11","doi-asserted-by":"publisher","first-page":"11725","DOI":"10.1073\/pnas.0402374101","volume":"101","author":"MW Neff","year":"2004","unstructured":"Neff MW, Robertson KR, Wong AK, Safra N, Broman KW, Slatkin M, et al. Breed distribution and history of canine mdr1\u20131Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci U S A. 2004;101:11725\u201330. https:\/\/doi.org\/10.1073\/pnas.0402374101.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6795_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2460\/javma.233.6.921","volume":"233","author":"KL Mealey","year":"2008","unstructured":"Mealey KL, Meurs KM. Breed distribution of the ABCB1-1Delta (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc. 2008;233:921\u20134. https:\/\/doi.org\/10.2460\/javma.233.6.921.","journal-title":"J Am Vet Med Assoc"},{"key":"6795_CR13","doi-asserted-by":"publisher","unstructured":"Merola VM, Eubig PA. Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of P-glycoprotein in dogs and cats. Vet Clin North Am Small Anim Pract. 2012;42:313\u201333, vii; https:\/\/doi.org\/10.1016\/j.cvsm.2011.12.005.","DOI":"10.1016\/j.cvsm.2011.12.005"},{"key":"6795_CR14","unstructured":"21 CFR Part 58: Good Laboratory Practice for Nonclinical Laboratory Studies Reference. U.S. Government Printing Office via GPO Access. 2005. 2005."},{"key":"6795_CR15","unstructured":"Guideline on target animal safety for veterinary pharmaceutical products. 2008."},{"key":"6795_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2460\/javma.1991.199.04.457","volume":"199","author":"PE Fassler","year":"1991","unstructured":"Fassler PE, Tranquilli WJ, Paul AJ, Soll MD, DiPietro JA, Todd KS. Evaluation of the safety of ivermectin administered in a beef-based formulation to ivermectin-sensitive Collies. J Am Vet Med Assoc. 1991;199:457\u201360.","journal-title":"J Am Vet Med Assoc"},{"key":"6795_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/bdd.313","volume":"23","author":"SR Vanapalli","year":"2002","unstructured":"Vanapalli SR, Hung YP, Fleckenstein L, Dzimianski MT, McCall JW. Pharmacokinetics and dose proportionality of oral moxidectin in beagle dogs. Biopharm Drug Dispos. 2002;23:263\u201372. https:\/\/doi.org\/10.1002\/bdd.313.","journal-title":"Biopharm Drug Dispos"},{"key":"6795_CR18","unstructured":"Riggs KL, Wiseman S, Wang X, Fraatz K. Long-term safety of Credelio Quattro\u2122 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), a novel orally administered combination endectocide for dogs. In press."},{"key":"6795_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijpddr.2019.06.002","volume":"10","author":"RK Prichard","year":"2019","unstructured":"Prichard RK, Geary TG. Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2019;10:69\u201383. https:\/\/doi.org\/10.1016\/j.ijpddr.2019.06.002.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"6795_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/s13071-017-2475-z","volume":"10","author":"CE Toutain","year":"2017","unstructured":"Toutain CE, Seewald W, Jung M. The intravenous and oral pharmacokinetics of lotilaner in dogs. Parasit Vectors. 2017;10:522. https:\/\/doi.org\/10.1186\/s13071-017-2475-z.","journal-title":"Parasit Vectors"},{"key":"6795_CR21","unstructured":"SUMMARY FOI: NADA 141-521 Simparica TRIO\u00ae(sarolaner, moxidectin, and pyrantel chewable tablets) Chewable Tablet Dogs. 2021."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-025-06795-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-025-06795-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-025-06795-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:39:43Z","timestamp":1745426383000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-025-06795-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6795"],"URL":"https:\/\/doi.org\/10.1186\/s13071-025-06795-y","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was based on the guidelines for evaluating the target animal safety of new pharmaceuticals: VICH Guideline 43, and to recognized quality assurance standards (United States Food and Drug Administration (FDA) Good Laboratory Practice (GLP) Regulations, 21 Code of Federal Regulations (CFR) Part 58, and the Organisation for Economic Cooperation and Development (OECD) Series on Principles of Good Laboratory Practice). The study was reviewed and approved by both CHK\u2019s and Elanco\u2019s Institutional Animal Care and Use Committee. This manuscript was prepared in compliance with the ARRIVE Guidelines Checklist for animal in vivo experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"These studies were funded by Elanco Animal Health. All authors are employees of Elanco Animal Health.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}